Received by email:

File: '\\doc\emailin\20210122 191035 Attachment Press Release_Kaly_FFCTO revocation v3.docx'



24599957.1




Kalytera Announces Revocation of FFCTO 

SAN FRANCISCO, CA -- (January 22, 2021) - Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company"
---> or "Kalytera") today announces that its previously announced cease trade order has been revoked. 

On June 22, 2020, the British Columbia Securities Commission (the "BCSC") and the Ontario Securities Commission (the "
--->OSC") issued a Failure-to-File Cease Trade Order against the Company (the "FFCTO") due to the Company's failure to fil
--->e by the prescribed filing deadlines its annual financial statements for the year ending December 31, 2019, and the ac
--->companying Management's Discussion and Analysis and certifications. As a result, the TSXV also suspended trading of th
--->e Company's common shares. The Company's auditor, BDO, has now completed the audit of the Company's financial statemen
--->ts for the year ended December 31, 2019, and the Company has now filed the audited financial statements for 2019, the 
--->quarterly financial statements for Q1 2020 (for period ending in March 31, 2020), Q2 2020 (for period ending in June 3
--->0, 2020) and Q3 2020 (for period ending in September 30, 2020) , and the accompanying Management's Discussion and Anal
--->ysis and certifications for all three periods (the "Filings"). The Company applied to the BCSC and the OSC on November
---> 4, 2020 to have the FFCTO fully revoked, and has applied to the TSXV on October 30, 2020 to have the Company's shares
---> resume trading after the FFCTO has been fully revoked. The BCSC and the OSC granted the full revocation with respect 
--->of the FFCTO on January 22, 2021. The Company is following up with the TSXV to remove its suspension and resume the tr
--->ading of the Company's common shares, which resumption when effected will be confirmed in a follow up press release. 

The Company confirms that its business has not changed, the Company remains active, and there are no changes to its cu
--->rrent business plans.

About Kalytera Therapeutics
Kalytera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing th
--->erapies for patients with significant unmet medical needs.

Website Home: https://kalytera.co/
News and Insights: https://kalytera.co/news/
Investors: https://kalytera.co/investors/

Cautionary Statements
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX 
--->Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release may contain 
--->certain forward-looking information and statements ("forward-looking information") within the meaning of applicable Ca
--->nadian securities legislation, that are not based on historical fact, in particular with respect of any implications t
--->he removal of the FFCTO and the resumption of trading of the securities of the Company may have.  The impact of the re
--->sumption of such trading (if any) is unknown and Kalytera undertakes no obligation to comment on analyses, expectation
--->s or statements made by third parties, its securities, or financial or operating results (as applicable). Kalytera dis
--->claims any intention and has no obligation or responsibility, except as required by law, to update or revise any forwa
--->rd-looking information, whether as a result of new information, future events or otherwise. 

Contact Information
Robert Farrell
President, CEO
(888) 861-2008
info@kalytera.co